Danish drugmaker Novo Nordisk plans to invest 8.5 billion Danish kroner (about €1.14 billion) to establish a new production facility in Odense, Denmark.
The new site will feature a finished production facility and warehouse spanning over 40,000 m2. Designed to be modular and flexible, it will accommodate multiple product types within rare disease, such as haemophilia, both now and in the future, Novo Nordisk said.
“The facility will utilize advanced technology and innovative equipment to ensure the highest quality to patients and meet the growing global demand for our life-changing medicines,” commented Henrik Wulff, executive vice president, Product Supply, Quality & IT of Novo Nordisk. “We are proud to build on our heritage in Denmark and look forward to embarking on this journey in Odense, a well-connected city with a dynamic community and talented workforce.”
According to Novo Nordisk, construction work has started and is scheduled to be completed in 2027. The investment is expected to create 400 permanent jobs upon completion of the facilities.
The company stated that more than 4,000 new trees will be planted at the site and buildings will be equipped with solar panels to enhance on-site electricity generation. The landscape will be designed by reusing excess soil, wooden materials and other sustainable resources to create lakes, forests and community spaces open to the public.
Source: chemanager-online.com
LEO Pharma has agreed to buy the worldwide rights to Tanabe Pharma’s drug in development for photosensitive genetic disorder treatment, bolstering the Danish company’s pipeline that has already undergone expansion this year.
Merck & Co. and Moderna announced encouraging results from a large clinical trial testing a new, personalized cancer treatment for melanoma, a serious form of skin cancer. The treatment, called intismeran, is made individually for each patient using their own tumor’s DNA. It’s designed to teach the immune system to recognize and attack cancer cells unique to that person.
Eurofins laboratories are supported by a dedicated analytical laboratory and an adjacent GMP warehouse, creating an integrated setup spanning development, analytical support, material management, and manufacturing readiness.
